A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
- PMID: 33976895
- PMCID: PMC8103737
- DOI: 10.1016/j.nmni.2021.100895
A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
Abstract
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae. Homology between hepatitis C virus RNA polymerase and severe acute respiratory syndrome coronavirus 2 has also been established. The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized.
Keywords: COVID-19; HCV; SARS-CoV-2; daclatasvir; sofosbuvir.
© 2021 The Authors.
References
-
- Thuluvath P., Guidinger M., Fung J., Johnson L., Rayhill S., Pelletier S. Liver transplantation in the United States, 1999–2008. Am J Transplant. 2010;10(4p2):1003–1019. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous